Crescent Biopharma (CBIO) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 89.4% versus a gain of 17.1%. Over five years, PBYI leads with a +64.8% price change compared with -92.9% for CBIO. Crescent Biopharma is the larger company by market cap ($524.5 million vs $514.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | PBYI |
|---|---|---|
| Share price | $14.12 | $9.97 |
| Market cap | $524.51M | $514.65M |
| 1-day change | +4.67% | +1.63% |
| YTD return | +19.06% | +64.87% |
| 1-year return | +17.08% | +89.38% |
| 5-year return | -92.87% | +64.79% |
| P/E ratio (TTM) | — | 19.55 |
| Forward P/E | — | 28.49 |
| EPS (TTM) | $-7.63 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $10.10 |
| 52-week low | $8.72 | $4.58 |
| Distance from 52-week high | -48.49% | -1.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +123.09% | — |
| Average volume | 397.58K | 322.37K |
| Shares outstanding | 37.14M | 51.62M |
| Employees | 69 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed CBIO by 72.3 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
CBIO vs PBYI FAQ
Which is bigger, Crescent Biopharma or Puma Biotechnology?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $524.51M compared with $514.65M for Puma Biotechnology (PBYI).
Which stock has performed better over the past year, CBIO or PBYI?
PBYI returned +89.38% over the past 12 months, compared with +17.08% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.